Prevalence of thyroid hormone abnormalities in stage 5 chronic kidney disease: a tertiary care center study of Nepal


  • Samir Singh Department of Clinical Biochemistry, KIST Medical College, Lalitpur
  • Aman Verma School of Life and Basic Sciences, Jaipur National, University, Jaipur, Rajasthan
  • Gopi Aryal Department of Pathology, KIST Medical College, Lalitpur
  • Santosh Thapa Department of Nephrology, KIST Medical College, Lalitpur



Chronic kidney disease, Thyroid hormone abnormalities, Nepal


Background: Chronic kidney disease (CKD) implies progressive, long-standing and irreversible impairment in renal function that results in end stage renal disease (ESRD). ESRD is a frequent cause of Non-thyroidal illness (NTI) with low free triidothyronine (fT3), usually elevated reverse T3 (rT3), normal or low thyroid stimulating hormone (TSH), and if prolonged, low free thyroxine (fT4), despite patient remaining clinically euthyroid. Present study aimed to estimate the prevalence of thyroid hormone abnormalities in stage 5 CKD patients and also to compare these changes with healthy controls.

Methods: The present cross-sectional observational study was conducted on thirty eight stage 5 CKD patients and 38 age-sexes matched healthy volunteers as control. The demographic data, medical history, etiology, physical examination and laboratory results were recorded on a special form developed by the researchers.

Results: The mean age of male and female stage 5 CKD patients were 50.81±17.30. 44.73% of the stage 5 CKD patients had low fT3 whereas 28.94% had low fT4 values below the reference range. 5.26% patients had increased TSH values above the normal reference limit. The mean TSH values were not significantly differing among diseased and control groups. Among the risk factors for CKD, diabetic nephropathy (44.73%) was found to be the lead primary cause followed by chronic glomerulonephritis (26.31%) and hypertension (21.05%).

Conclusions: From this study, it was concluded that the prevalence of thyroid hormone abnormalities especially low fT3 and fT4 is very common in stage 5 CKD patients. Diabetic nephropathy was among the lead cause of stage 5 CKD.


Kumar P, Clark M. Clinical Medicine. 7th ed. (UK). Elsevier Limited. 2009:625-6.

Parmar MS. Chronic renal disease. BMJ. 2002;325(7355):85-90.

Vasudevan DM, Sreekumari S. Textbook of Biochemistry. 7th ed. New Delhi (India). Jaypee Brothers Medical Publishers (P) Ltd. 2013:674-5.

Ramirez G, O'Neill W, Jubiz W, Bloomer HA. Thyroid dysfunction in uremia: evidence for thyroid and hypophyseal abnormalities. Ann Int Med. 1996;84:672-6.

Majeed HM, Mohammed MR, AL-Wandi NKMA, Ibrahim FA. Association between chronic renal failure and thyroid hormone. Diyala Journal of Medicine. 2012;3(1):62-6.

Iglesias P, Dıez JJ. Thyroid dysfunction and kidney disease. Eur J Endocrinol. 2009;160(4):503-15.

DeGroot LJ. NCBI Bookself. Available at books/ NBK 285570/ Accessed 9 March 2016

Fauci AS, Braunwald E, Kasper DL, Hauser SL, Longo DL. Harrison’s Principles of Internal Medicine.17th ed. McGraw-Hill Medical Publishing Division, New York (USA). 2007.

Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. American Journal of Nephrology. 1982;2:70-6.

Singh PA, Bobby Z, Selvaraj N, Vinayagamoorti R. An evaluation of thyroid hormone status and oxidative stress in undialyzed chronic renal failure patients. Indian J Physiol Pharmacol. 2006;50(3):279-84.

Rajagopalan B, Dolla PB, Arumalla VK, Reddy VS. Renal function markers and thyroid hormone status in undialyzed chronic kidney disease. Al Ameen J Med Sci. 2013;6(1):70-4.

Kaptein EM, Quinon-Verde H, Choolijian CJ, Tang WW, Friedman PE, Rodriquez HJ, Massry SG. The thyroid in end stage renal disease. Medicine (Baltimore). 1988;67(3):187-97.

Layla KA. The Effect of Chronic Renal Failure on Thyroid Homone, Iraqi J pharm Sci. 2010;19(1):65-8.

Lim VS. Thyroid function in patients with chronic renal failure. Am. J Kidney Dis. 2001;38:S80-4.

Basu G, Mohapatra A. “Interactions between thyroid disorders and kidney disease,” Indian Journal of Endocrinology and Metabolism 2012;16:204-13.

Lim VS, Fang VS, Katz AI, Refetoff S. Thyroid dysfunction in chronic renal failure. A study of the pituitary thyroid axis and peripheral turnover kinetics of thyroxine and triiodothyronine. Journal of Clinical Investigation. 1977;60:522-34.

Horacek J, Sulkova S, Kubisova M, Safranek R, Malirova E, Kalousova M et al. Thyroid hormone abnormalities in hemodialyzed patients: Low triidothyronine as well as high reverse triidothyronine are associated with increased mortality. Physiol. Res. 2012;61:495-501.

KC Shiva Raj. Thyroid function tests and its interpretation. Journal of Pathology of Nepal. 2014;4:584-90.

Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol. 2008;3:1296-300.

Foley RN, Collins AJ. End-Stage Renal Disease in the United States: An Update from the United States Renal Data System. J Am Soc Nephrol. 2007;18:2644-8.

Marshall SM. Recent advances in diabetic nephropathy. Postgrad Med J. 2004;80:624-33.

Khakurel S, Agrawal RK, Hada R. Pattern of End Stage Renal Disease in a Tertiary Care Center. J Nepal Med Assoc. 2009;48:126-30.




How to Cite

Singh, S., Verma, A., Aryal, G., & Thapa, S. (2016). Prevalence of thyroid hormone abnormalities in stage 5 chronic kidney disease: a tertiary care center study of Nepal. International Journal of Research in Medical Sciences, 4(9), 3929–3933.



Original Research Articles